Scholarlink

<p>Weekly paclitaxel and trastuzumab (APT regimen) represents the standard treatment for most stage I HER2+ breast cancer (BC) patients based on results of the single arm phase II APT trial. Confirmation of long-term outcomes in real-world cohorts is of interest. This retrospective study included patients with early HER2 + BC (pT ≤ 3 cm; pN0/N1mic) treated with APT regimen. This study included 276 patients; most presented hormone receptor (HR) positive (75%, <i>N</i> = 207) and grade 3 tumors (65.6%, <i>N</i> = 181). The majority had pT ≤ 2 cm (92.4%, <i>N</i> = 255), no nodal involvement (93.1%, <i>N</i> = 257), with only 19 patients (6.9%) presenting N1mic. Anatomical stage was: IA 86.2% (<i>N</i> = 238), IB 6.2% (<i>N</i> = 17), and IIA 7.6% (<i>N</i> = 21). At a median follow-up of 4.4 years, 3-year recurrence free survival (RFS) was 97.3% (95% CI 95.1–99.5), 3-year distant relapse free survival (DRFS) was 98.2% (95% CI 96.4–100), and 3-year invasive breast cancer free survival (IBCFS) rate was 97.1% (95% CI 94.7–99.5). A statistically significant difference in RFS was observed according to anatomical stage ( <i>p</i> &lt; 0.001). This real-world study confirms that APT regimen is associated with excellent outcomes in stage IA HER2 + BC patients, while caution is warranted for patients with stage IB or IIA disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月26日

查看全文
  • Giorgio Bonomi,
  • Gaia Griguolo,
  • Tommaso Giarratano,
  • Francesca Zanghì,
  • Davide Napetti,
  • Cristina Falci,
  • Federica Miglietta,
  • Massimo Ferrucci,
  • Giovanni Faggioni,
  • Grazia Maria Vernaci,
  • Michele Bottosso,
  • Aleix Prat,
  • Maria Vittoria Dieci,
  • Valentina Guarneri

摘要

Weekly paclitaxel and trastuzumab (APT regimen) represents the standard treatment for most stage I HER2+ breast cancer (BC) patients based on results of the single arm phase II APT trial. Confirmation of long-term outcomes in real-world cohorts is of interest. This retrospective study included patients with early HER2 + BC (pT ≤ 3 cm; pN0/N1mic) treated with APT regimen. This study included 276 patients; most presented hormone receptor (HR) positive (75%, N = 207) and grade 3 tumors (65.6%, N = 181). The majority had pT ≤ 2 cm (92.4%, N = 255), no nodal involvement (93.1%, N = 257), with only 19 patients (6.9%) presenting N1mic. Anatomical stage was: IA 86.2% (N = 238), IB 6.2% (N = 17), and IIA 7.6% (N = 21). At a median follow-up of 4.4 years, 3-year recurrence free survival (RFS) was 97.3% (95% CI 95.1–99.5), 3-year distant relapse free survival (DRFS) was 98.2% (95% CI 96.4–100), and 3-year invasive breast cancer free survival (IBCFS) rate was 97.1% (95% CI 94.7–99.5). A statistically significant difference in RFS was observed according to anatomical stage ( p < 0.001). This real-world study confirms that APT regimen is associated with excellent outcomes in stage IA HER2 + BC patients, while caution is warranted for patients with stage IB or IIA disease.